Publications by authors named "B Mise"
Ceftriaxone upregulates GLT1 glutamate transporter in the brain and may have anti-CFC and anti-OCD effects. Twenty WZ-5HT rats were used to investigate the effects of ceftriaxone on obsessive-compulsive (OCD)-like behaviour in the marble-burying (MB) test, freezing behaviour in contextual fear conditioning (CFC) and expression of GLT1 protein in the hippocampus or amygdala using immunoblots. Fifteen DBA/2J mice were used in the MB test.
View Article and Find Full Text PDFSelective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed medications for the treatment of mood disorders. Yet, individual response to SSRIs is highly variable, with only a portion of patients showing the desired therapeutic effect. To better understand the molecular basis underlying individual variability in response to SSRIs, here we comparatively studied behavioral and molecular consequences of chronic treatment with fluoxetine, a widely used SSRI, in two sublines of rats with constitutionally different serotonin (5HT) homeostasis: the high-5HT and low-5HT sublines.
View Article and Find Full Text PDFBackground: Our objective was to assess the effects of COVID-19 antiepidemic measures and subsequent changes in the function of the health care system on the number of newly diagnosed breast cancers in the Republic of Croatia.
Subjects, Materials, And Methods: We performed a retrospective, population- and registry-based study during 2020. The comparator was the number of patients newly diagnosed with breast cancer during 2017, 2018, and 2019.
Article Synopsis
- The study evaluated the safety and effectiveness of olaparib as maintenance therapy for patients with BRCA 1-2 mutated, platinum-sensitive recurrent ovarian cancer who had responded to previous platinum-based chemotherapy.
- Conducted in Croatia from 2016 to 2020, the study included 69 patients and monitored key outcomes like progression-free survival and treatment discontinuation due to side effects.
- Results showed that olaparib had a median progression-free survival of 21 months, with most patients experiencing some level of toxicity, but its safety and efficacy were consistent with previous clinical trials.
Aim: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2- metastatic breast cancer (mBC) in combination with hormonal therapy improve progression-free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear.
Methods: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented.